DK1534335T4 - FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF - Google Patents

Info

Publication number

DK1534335T4

DK1534335T4 DK03788456.6T DK03788456T DK1534335T4 DK 1534335 T4 DK1534335 T4 DK 1534335T4 DK 03788456 T DK03788456 T DK 03788456T DK 1534335 T4 DK1534335 T4 DK 1534335T4

Authority

DK

Denmark

Prior art keywords

antibody

antibodies

cells

fragment

fcyriib

Prior art date

2002-08-14

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title abstract description 226
• 239000012634 fragment Substances 0.000 claims abstract description 164
• 241000282414 Homo sapiens Species 0.000 claims abstract description 159
• 230000001225 therapeutic effect Effects 0.000 claims abstract description 94
• 239000000203 mixture Substances 0.000 claims abstract description 39
• 230000002708 enhancing effect Effects 0.000 claims abstract description 32
• 229960005486 vaccine Drugs 0.000 claims abstract description 24
• 206010028980 Neoplasm Diseases 0.000 claims description 286
• 201000011510 cancer Diseases 0.000 claims description 141
• 230000001404 mediated effect Effects 0.000 claims description 108
• 239000000427 antigen Substances 0.000 claims description 106
• 108091007433 antigens Proteins 0.000 claims description 105
• 102000036639 antigens Human genes 0.000 claims description 105
• 230000000694 effects Effects 0.000 claims description 101
• 230000027455 binding Effects 0.000 claims description 90
• 238000011282 treatment Methods 0.000 claims description 83
• 239000003814 drug Substances 0.000 claims description 54
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 50
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
• 230000004913 activation Effects 0.000 claims description 39
• 210000004408 hybridoma Anatomy 0.000 claims description 39
• 210000003630 histaminocyte Anatomy 0.000 claims description 35
• 229920001184 polypeptide Polymers 0.000 claims description 35
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 34
• 230000011664 signaling Effects 0.000 claims description 34
• 230000001419 dependent effect Effects 0.000 claims description 32
• 230000001472 cytotoxic effect Effects 0.000 claims description 30
• 229940124597 therapeutic agent Drugs 0.000 claims description 25
• 108091008875 B cell receptors Proteins 0.000 claims description 24
• 230000004048 modification Effects 0.000 claims description 24
• 238000012986 modification Methods 0.000 claims description 24
• 231100000433 cytotoxic Toxicity 0.000 claims description 23
• 230000028993 immune response Effects 0.000 claims description 21
• 238000004519 manufacturing process Methods 0.000 claims description 20
• -1 GAGE-2 Proteins 0.000 claims description 18
• 229940079593 drug Drugs 0.000 claims description 18
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 16
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
• 230000020411 cell activation Effects 0.000 claims description 15
• 230000019491 signal transduction Effects 0.000 claims description 11
• 230000007783 downstream signaling Effects 0.000 claims description 9
• 210000005260 human cell Anatomy 0.000 claims description 9
• 230000003834 intracellular effect Effects 0.000 claims description 9
• 239000008194 pharmaceutical composition Substances 0.000 claims description 8
• 230000004663 cell proliferation Effects 0.000 claims description 7
• 230000022534 cell killing Effects 0.000 claims description 6
• 230000036755 cellular response Effects 0.000 claims description 6
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 5
• 108010001857 Cell Surface Receptors Proteins 0.000 claims description 4
• 102100034256 Mucin-1 Human genes 0.000 claims description 4
• 108010008707 Mucin-1 Proteins 0.000 claims description 4
• 230000009460 calcium influx Effects 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
• 239000002619 cytotoxin Substances 0.000 claims description 3
• 101710112752 Cytotoxin Proteins 0.000 claims description 2
• 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 3
• 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 3
• 241000701806 Human papillomavirus Species 0.000 claims 2
• 102000006240 membrane receptors Human genes 0.000 claims 2
• 101800000504 3C-like protease Proteins 0.000 claims 1
• 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 claims 1
• 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
• 102000015735 Beta-catenin Human genes 0.000 claims 1
• 108060000903 Beta-catenin Proteins 0.000 claims 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
• 102100039717 G antigen 1 Human genes 0.000 claims 1
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
• 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims 1
• 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 claims 1
• 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 1
• 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims 1
• 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 1
• 101800000607 p15 Proteins 0.000 claims 1
• 239000012636 effector Substances 0.000 abstract description 74
• 210000004027 cell Anatomy 0.000 description 322
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 72
• 108090000623 proteins and genes Proteins 0.000 description 69
• 238000003556 assay Methods 0.000 description 65
• 102000005962 receptors Human genes 0.000 description 53
• 108020003175 receptors Proteins 0.000 description 53
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 50
• 210000004881 tumor cell Anatomy 0.000 description 50
• 241000699670 Mus sp. Species 0.000 description 46
• 210000001616 monocyte Anatomy 0.000 description 44
• 230000014509 gene expression Effects 0.000 description 43
• 235000018102 proteins Nutrition 0.000 description 43
• 102000004169 proteins and genes Human genes 0.000 description 43
• 230000006870 function Effects 0.000 description 41
• 208000035475 disorder Diseases 0.000 description 40
• 208000023275 Autoimmune disease Diseases 0.000 description 39
• 239000003795 chemical substances by application Substances 0.000 description 38
• 230000026731 phosphorylation Effects 0.000 description 38
• 238000006366 phosphorylation reaction Methods 0.000 description 38
• 108060003951 Immunoglobulin Proteins 0.000 description 37
• 102000018358 immunoglobulin Human genes 0.000 description 37
• 235000001014 amino acid Nutrition 0.000 description 35
• 125000003275 alpha amino acid group Chemical group 0.000 description 34
• 201000010099 disease Diseases 0.000 description 32
• 150000001720 carbohydrates Chemical class 0.000 description 31
• 230000005764 inhibitory process Effects 0.000 description 27
• 210000002540 macrophage Anatomy 0.000 description 27
• 230000002401 inhibitory effect Effects 0.000 description 26
• 230000002265 prevention Effects 0.000 description 25
• 230000000069 prophylactic effect Effects 0.000 description 25
• 108020004414 DNA Proteins 0.000 description 24
• 241000699666 Mus <mouse, genus> Species 0.000 description 24
• 206010039073 rheumatoid arthritis Diseases 0.000 description 24
• 241000283707 Capra Species 0.000 description 22
• 206010020751 Hypersensitivity Diseases 0.000 description 22
• 238000006467 substitution reaction Methods 0.000 description 22
• 239000013598 vector Substances 0.000 description 22
• 206010003445 Ascites Diseases 0.000 description 21
• 229940024606 amino acid Drugs 0.000 description 21
• 230000009089 cytolysis Effects 0.000 description 21
• 150000007523 nucleic acids Chemical group 0.000 description 21
• 230000001270 agonistic effect Effects 0.000 description 20
• 235000014633 carbohydrates Nutrition 0.000 description 20
• 125000000539 amino acid group Chemical group 0.000 description 19
• 150000001413 amino acids Chemical class 0.000 description 19
• 208000027866 inflammatory disease Diseases 0.000 description 19
• 102000039446 nucleic acids Human genes 0.000 description 19
• 108020004707 nucleic acids Proteins 0.000 description 19
• 239000000126 substance Substances 0.000 description 19
• 102000037865 fusion proteins Human genes 0.000 description 18
• 108020001507 fusion proteins Proteins 0.000 description 18
• 238000001727 in vivo Methods 0.000 description 18
• 230000001965 increasing effect Effects 0.000 description 18
• 210000001519 tissue Anatomy 0.000 description 18
• 206010057249 Phagocytosis Diseases 0.000 description 17
• 230000000172 allergic effect Effects 0.000 description 17
• 208000010668 atopic eczema Diseases 0.000 description 17
• 230000000903 blocking effect Effects 0.000 description 17
• 210000004369 blood Anatomy 0.000 description 17
• 239000008280 blood Substances 0.000 description 17
• 230000010534 mechanism of action Effects 0.000 description 17
• 125000003729 nucleotide group Chemical group 0.000 description 17
• 230000008782 phagocytosis Effects 0.000 description 17
• 230000004044 response Effects 0.000 description 17
• 102000009109 Fc receptors Human genes 0.000 description 16
• 108010087819 Fc receptors Proteins 0.000 description 16
• 208000009956 adenocarcinoma Diseases 0.000 description 16
• 230000003042 antagnostic effect Effects 0.000 description 16
• 238000005516 engineering process Methods 0.000 description 16
• 230000004054 inflammatory process Effects 0.000 description 16
• 201000001441 melanoma Diseases 0.000 description 16
• 239000002773 nucleotide Substances 0.000 description 16
• 108091033319 polynucleotide Proteins 0.000 description 16
• 102000040430 polynucleotide Human genes 0.000 description 16
• 239000002157 polynucleotide Substances 0.000 description 16
• 208000026310 Breast neoplasm Diseases 0.000 description 15
• 206010061218 Inflammation Diseases 0.000 description 15
• 206010033128 Ovarian cancer Diseases 0.000 description 15
• 230000003213 activating effect Effects 0.000 description 15
• 208000026935 allergic disease Diseases 0.000 description 15
• 239000013604 expression vector Substances 0.000 description 15
• 206010006187 Breast cancer Diseases 0.000 description 14
• 238000002965 ELISA Methods 0.000 description 14
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 14
• 239000002671 adjuvant Substances 0.000 description 14
• 210000003651 basophil Anatomy 0.000 description 14
• 230000013595 glycosylation Effects 0.000 description 14
• 238000006206 glycosylation reaction Methods 0.000 description 14
• 239000006228 supernatant Substances 0.000 description 14
• 241001465754 Metazoa Species 0.000 description 13
• 230000000259 anti-tumor effect Effects 0.000 description 13
• 206010003246 arthritis Diseases 0.000 description 13
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
• 206010027476 Metastases Diseases 0.000 description 12
• 230000007815 allergy Effects 0.000 description 12
• 230000001413 cellular effect Effects 0.000 description 12
• 230000009401 metastasis Effects 0.000 description 12
• 238000011275 oncology therapy Methods 0.000 description 12
• 230000007115 recruitment Effects 0.000 description 12
• 238000010561 standard procedure Methods 0.000 description 12
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 12
• 241001529936 Murinae Species 0.000 description 11
• 241000699660 Mus musculus Species 0.000 description 11
• 241000700605 Viruses Species 0.000 description 11
• 239000002246 antineoplastic agent Substances 0.000 description 11
• 230000006907 apoptotic process Effects 0.000 description 11
• 238000004132 cross linking Methods 0.000 description 11
• 230000002519 immonomodulatory effect Effects 0.000 description 11
• 208000015181 infectious disease Diseases 0.000 description 11
• 210000001503 joint Anatomy 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 11
• 238000003127 radioimmunoassay Methods 0.000 description 11
• 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 11
• 238000002560 therapeutic procedure Methods 0.000 description 11
• 238000012286 ELISA Assay Methods 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 108010073816 IgE Receptors Proteins 0.000 description 10
• 102000009438 IgE Receptors Human genes 0.000 description 10
• 206010061535 Ovarian neoplasm Diseases 0.000 description 10
• 239000002260 anti-inflammatory agent Substances 0.000 description 10
• 229940121363 anti-inflammatory agent Drugs 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 230000003993 interaction Effects 0.000 description 10
• 125000005647 linker group Chemical group 0.000 description 10
• 210000004980 monocyte derived macrophage Anatomy 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 208000024891 symptom Diseases 0.000 description 10
• 101150029707 ERBB2 gene Proteins 0.000 description 9
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 9
• 241000124008 Mammalia Species 0.000 description 9
• 210000000481 breast Anatomy 0.000 description 9
• 238000002512 chemotherapy Methods 0.000 description 9
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 9
• 229940127089 cytotoxic agent Drugs 0.000 description 9
• 230000006378 damage Effects 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 238000009396 hybridization Methods 0.000 description 9
• 230000003053 immunization Effects 0.000 description 9
• 238000009169 immunotherapy Methods 0.000 description 9
• 238000002347 injection Methods 0.000 description 9
• 239000007924 injection Substances 0.000 description 9
• 208000032839 leukemia Diseases 0.000 description 9
• 210000005170 neoplastic cell Anatomy 0.000 description 9
• 230000003389 potentiating effect Effects 0.000 description 9
• 238000012216 screening Methods 0.000 description 9
• 206010041823 squamous cell carcinoma Diseases 0.000 description 9
• 238000011830 transgenic mouse model Methods 0.000 description 9
• 201000009030 Carcinoma Diseases 0.000 description 8
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 8
• 102100037832 Docking protein 1 Human genes 0.000 description 8
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
• 101000805172 Homo sapiens Docking protein 1 Proteins 0.000 description 8
• 206010025323 Lymphomas Diseases 0.000 description 8
• 108091054455 MAP kinase family Proteins 0.000 description 8
• 102000043136 MAP kinase family Human genes 0.000 description 8
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 8
• 206010042674 Swelling Diseases 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 8
• 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 8
• 230000002950 deficient Effects 0.000 description 8
• 239000003550 marker Substances 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 238000012552 review Methods 0.000 description 8
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
• 230000008961 swelling Effects 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 102000004127 Cytokines Human genes 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 7
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
• 241000283973 Oryctolagus cuniculus Species 0.000 description 7
• 208000002151 Pleural effusion Diseases 0.000 description 7
• 241000276498 Pollachius virens Species 0.000 description 7
• 108020004511 Recombinant DNA Proteins 0.000 description 7
• 210000001744 T-lymphocyte Anatomy 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 210000000845 cartilage Anatomy 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 210000000987 immune system Anatomy 0.000 description 7
• 230000002163 immunogen Effects 0.000 description 7
• 230000001939 inductive effect Effects 0.000 description 7
• 230000036210 malignancy Effects 0.000 description 7
• 230000003211 malignant effect Effects 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 229960000485 methotrexate Drugs 0.000 description 7
• 150000002482 oligosaccharides Chemical class 0.000 description 7
• 230000002611 ovarian Effects 0.000 description 7
• 238000002823 phage display Methods 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 230000028327 secretion Effects 0.000 description 7
• 238000010186 staining Methods 0.000 description 7
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 6
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 6
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 6
• 108091026890 Coding region Proteins 0.000 description 6
• 101150064015 FAS gene Proteins 0.000 description 6
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 239000004698 Polyethylene Substances 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• 208000003837 Second Primary Neoplasms Diseases 0.000 description 6
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 230000001640 apoptogenic effect Effects 0.000 description 6
• 230000001363 autoimmune Effects 0.000 description 6
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 6
• 238000012512 characterization method Methods 0.000 description 6
• 230000001086 cytosolic effect Effects 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 210000002950 fibroblast Anatomy 0.000 description 6
• 238000003018 immunoassay Methods 0.000 description 6
• 229940072221 immunoglobulins Drugs 0.000 description 6
• 230000002757 inflammatory effect Effects 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 230000004936 stimulating effect Effects 0.000 description 6
• 238000007920 subcutaneous administration Methods 0.000 description 6
• 235000000346 sugar Nutrition 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 5
• 102000001301 EGF receptor Human genes 0.000 description 5
• 108060006698 EGF receptor Proteins 0.000 description 5
• 201000008808 Fibrosarcoma Diseases 0.000 description 5
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
• 102000014150 Interferons Human genes 0.000 description 5
• 108010050904 Interferons Proteins 0.000 description 5
• 108010002350 Interleukin-2 Proteins 0.000 description 5
• 102000000588 Interleukin-2 Human genes 0.000 description 5
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 5
• 230000004988 N-glycosylation Effects 0.000 description 5
• 208000002193 Pain Diseases 0.000 description 5
• 206010039491 Sarcoma Diseases 0.000 description 5
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
• 238000002835 absorbance Methods 0.000 description 5
• 208000006673 asthma Diseases 0.000 description 5
• 239000011324 bead Substances 0.000 description 5
• 210000000988 bone and bone Anatomy 0.000 description 5
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 230000016396 cytokine production Effects 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 238000003745 diagnosis Methods 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 210000003743 erythrocyte Anatomy 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• 238000007726 management method Methods 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 210000000822 natural killer cell Anatomy 0.000 description 5
• 230000014207 opsonization Effects 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 238000001959 radiotherapy Methods 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 210000003491 skin Anatomy 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 230000004614 tumor growth Effects 0.000 description 5
• 238000005406 washing Methods 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
• 206010002198 Anaphylactic reaction Diseases 0.000 description 4
• 241000972773 Aulopiformes Species 0.000 description 4
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
• KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 4
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
• 241000759568 Corixa Species 0.000 description 4
• 108010092160 Dactinomycin Proteins 0.000 description 4
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 4
• 229920001917 Ficoll Polymers 0.000 description 4
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 4
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 4
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
• 102100030931 Ladinin-1 Human genes 0.000 description 4
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• 101150018665 MAPK3 gene Proteins 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 230000021736 acetylation Effects 0.000 description 4
• 238000006640 acetylation reaction Methods 0.000 description 4
• 230000033289 adaptive immune response Effects 0.000 description 4
• 239000013566 allergen Substances 0.000 description 4
• 230000004075 alteration Effects 0.000 description 4
• 230000036783 anaphylactic response Effects 0.000 description 4
• 208000003455 anaphylaxis Diseases 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 229910052791 calcium Inorganic materials 0.000 description 4
• 230000003915 cell function Effects 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 230000001268 conjugating effect Effects 0.000 description 4
• 230000021615 conjugation Effects 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 238000012258 culturing Methods 0.000 description 4
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 4
• 229960004679 doxorubicin Drugs 0.000 description 4
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 4
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
• WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• 230000003394 haemopoietic effect Effects 0.000 description 4
• 238000001794 hormone therapy Methods 0.000 description 4
• 239000012642 immune effector Substances 0.000 description 4
• 230000016784 immunoglobulin production Effects 0.000 description 4
• 229940121354 immunomodulator Drugs 0.000 description 4
• 230000015788 innate immune response Effects 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 229940079322 interferon Drugs 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 206010025135 lupus erythematosus Diseases 0.000 description 4
• 230000001613 neoplastic effect Effects 0.000 description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
• 229920001542 oligosaccharide Polymers 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000001737 promoting effect Effects 0.000 description 4
• KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 239000012857 radioactive material Substances 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 235000019515 salmon Nutrition 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 229940076279 serotonin Drugs 0.000 description 4
• 210000004989 spleen cell Anatomy 0.000 description 4
• 239000007921 spray Substances 0.000 description 4
• 101150047061 tag-72 gene Proteins 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 3
• VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
• 108010006654 Bleomycin Proteins 0.000 description 3
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 3
• VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 3
• 108060005980 Collagenase Proteins 0.000 description 3
• 102000029816 Collagenase Human genes 0.000 description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 229910052693 Europium Inorganic materials 0.000 description 3
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• 102000005720 Glutathione transferase Human genes 0.000 description 3
• 108010070675 Glutathione transferase Proteins 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 108090000467 Interferon-beta Proteins 0.000 description 3
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
• 208000003456 Juvenile Arthritis Diseases 0.000 description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• 101710177601 Ladinin-1 Proteins 0.000 description 3
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
• 101150024075 Mapk1 gene Proteins 0.000 description 3
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• 206010061309 Neoplasm progression Diseases 0.000 description 3
• 230000004989 O-glycosylation Effects 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• 108010004729 Phycoerythrin Proteins 0.000 description 3
• 208000007452 Plasmacytoma Diseases 0.000 description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 3
• 108050004017 Ras GTPase-activating protein 1 Proteins 0.000 description 3
• 208000033464 Reiter syndrome Diseases 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 201000010208 Seminoma Diseases 0.000 description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 208000019790 abdominal distention Diseases 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
• 239000012190 activator Substances 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 230000002052 anaphylactic effect Effects 0.000 description 3
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 3
• 229940124599 anti-inflammatory drug Drugs 0.000 description 3
• 230000000340 anti-metabolite Effects 0.000 description 3
• 229940125715 antihistaminic agent Drugs 0.000 description 3
• 239000000739 antihistaminic agent Substances 0.000 description 3
• 229940100197 antimetabolite Drugs 0.000 description 3
• 239000002256 antimetabolite Substances 0.000 description 3
• 230000008512 biological response Effects 0.000 description 3
• 238000001815 biotherapy Methods 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 230000006369 cell cycle progression Effects 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• 230000006020 chronic inflammation Effects 0.000 description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 229960002424 collagenase Drugs 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• 229960001334 corticosteroids Drugs 0.000 description 3
• CZZLLDDFQKSALH-UHFFFAOYSA-N cpg 8954 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C(OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 CZZLLDDFQKSALH-UHFFFAOYSA-N 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• 231100000135 cytotoxicity Toxicity 0.000 description 3
• 238000002784 cytotoxicity assay Methods 0.000 description 3
• 231100000263 cytotoxicity test Toxicity 0.000 description 3
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 3
• 229960000640 dactinomycin Drugs 0.000 description 3
• 229960000975 daunorubicin Drugs 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 238000001212 derivatisation Methods 0.000 description 3
• 201000001981 dermatomyositis Diseases 0.000 description 3
• 238000012137 double-staining Methods 0.000 description 3
• 210000001671 embryonic stem cell Anatomy 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
• 230000003463 hyperproliferative effect Effects 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 210000004969 inflammatory cell Anatomy 0.000 description 3
• 238000011081 inoculation Methods 0.000 description 3
• 230000004068 intracellular signaling Effects 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 230000002934 lysing effect Effects 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 108010082117 matrigel Proteins 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
• 210000005033 mesothelial cell Anatomy 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 238000012544 monitoring process Methods 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 201000008968 osteosarcoma Diseases 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 230000001323 posttranslational effect Effects 0.000 description 3
• 229960005205 prednisolone Drugs 0.000 description 3
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000000644 propagated effect Effects 0.000 description 3
• 230000006337 proteolytic cleavage Effects 0.000 description 3
• 229960003908 pseudoephedrine Drugs 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 208000002574 reactive arthritis Diseases 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 230000006798 recombination Effects 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 238000009987 spinning Methods 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 210000001685 thyroid gland Anatomy 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 230000001960 triggered effect Effects 0.000 description 3
• 230000005751 tumor progression Effects 0.000 description 3
• 229960003048 vinblastine Drugs 0.000 description 3
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
• 229960004528 vincristine Drugs 0.000 description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 2
• VXPSQDAMFATNNG-UHFFFAOYSA-N 3-[2-(2,5-dioxopyrrol-3-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C(=CC=CC=2)C=2C(NC(=O)C=2)=O)=C1 VXPSQDAMFATNNG-UHFFFAOYSA-N 0.000 description 2
• NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 2
• 208000016557 Acute basophilic leukemia Diseases 0.000 description 2
• 201000003076 Angiosarcoma Diseases 0.000 description 2
• 102400000068 Angiostatin Human genes 0.000 description 2
• 108010079709 Angiostatins Proteins 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 208000036487 Arthropathies Diseases 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 2
• 230000003844 B-cell-activation Effects 0.000 description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 description 2
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
• 101001011741 Bos taurus Insulin Proteins 0.000 description 2
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
• 208000011691 Burkitt lymphomas Diseases 0.000 description 2
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
• 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 2
• 201000000274 Carcinosarcoma Diseases 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 241000701489 Cauliflower mosaic virus Species 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010039939 Cell Wall Skeleton Proteins 0.000 description 2
• ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 241000272194 Ciconiiformes Species 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 208000032170 Congenital Abnormalities Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
• 102000009058 Death Domain Receptors Human genes 0.000 description 2
• 108010049207 Death Domain Receptors Proteins 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 108010079505 Endostatins Proteins 0.000 description 2
• 208000001640 Fibromyalgia Diseases 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 101710154606 Hemagglutinin Proteins 0.000 description 2
• 208000001258 Hemangiosarcoma Diseases 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 108010078049 Interferon alpha-2 Proteins 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 208000012659 Joint disease Diseases 0.000 description 2
• 206010023230 Joint stiffness Diseases 0.000 description 2
• 208000018142 Leiomyosarcoma Diseases 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 2
• 108010063954 Mucins Proteins 0.000 description 2
• 102000015728 Mucins Human genes 0.000 description 2
• 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 2
• 101000686934 Mus musculus Prolactin-7D1 Proteins 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
• JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 208000010191 Osteitis Deformans Diseases 0.000 description 2
• 208000003076 Osteolysis Diseases 0.000 description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 208000027868 Paget disease Diseases 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 206010034277 Pemphigoid Diseases 0.000 description 2
• 102000057297 Pepsin A Human genes 0.000 description 2
• 108090000284 Pepsin A Proteins 0.000 description 2
• 208000031845 Pernicious anaemia Diseases 0.000 description 2
• 208000007641 Pinealoma Diseases 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 102000013566 Plasminogen Human genes 0.000 description 2
• 108010051456 Plasminogen Proteins 0.000 description 2
• 102000004211 Platelet factor 4 Human genes 0.000 description 2
• 108090000778 Platelet factor 4 Proteins 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 229920000388 Polyphosphate Polymers 0.000 description 2
• 102000003946 Prolactin Human genes 0.000 description 2
• 108010057464 Prolactin Proteins 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 101710176177 Protein A56 Proteins 0.000 description 2
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 206010039085 Rhinitis allergic Diseases 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 208000006045 Spondylarthropathies Diseases 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 108010046722 Thrombospondin 1 Proteins 0.000 description 2
• 102100036034 Thrombospondin-1 Human genes 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• SMPZPKRDRQOOHT-UHFFFAOYSA-N acronycine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 201000010105 allergic rhinitis Diseases 0.000 description 2
• 230000009435 amidation Effects 0.000 description 2
• 238000007112 amidation reaction Methods 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 230000000845 anti-microbial effect Effects 0.000 description 2
• 230000000840 anti-viral effect Effects 0.000 description 2
• 239000004599 antimicrobial Substances 0.000 description 2
• 230000005775 apoptotic pathway Effects 0.000 description 2
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 238000000376 autoradiography Methods 0.000 description 2
• 239000007640 basal medium Substances 0.000 description 2
• 229950000210 beclometasone dipropionate Drugs 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 229960001561 bleomycin Drugs 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 206010006007 bone sarcoma Diseases 0.000 description 2
• IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
• 201000008275 breast carcinoma Diseases 0.000 description 2
• 208000035269 cancer or benign tumor Diseases 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 229960005243 carmustine Drugs 0.000 description 2
• 229960000590 celecoxib Drugs 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 210000004520 cell wall skeleton Anatomy 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 229960004630 chlorambucil Drugs 0.000 description 2
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
• 239000011651 chromium Substances 0.000 description 2
• 208000019069 chronic childhood arthritis Diseases 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
• 201000010897 colon adenocarcinoma Diseases 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 229960000265 cromoglicic acid Drugs 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 239000002254 cytotoxic agent Substances 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• 230000006806 disease prevention Effects 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 229960003592 fexofenadine Drugs 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 229960000676 flunisolide Drugs 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 229960000289 fluticasone propionate Drugs 0.000 description 2
• 230000022244 formylation Effects 0.000 description 2
• 238000006170 formylation reaction Methods 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
• 229930182830 galactose Natural products 0.000 description 2
• 206010017758 gastric cancer Diseases 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 239000003862 glucocorticoid Substances 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• 229940022353 herceptin Drugs 0.000 description 2
• 229960001340 histamine Drugs 0.000 description 2
• 230000001744 histochemical effect Effects 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000036737 immune function Effects 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000004968 inflammatory condition Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 108091008042 inhibitory receptors Proteins 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
• 229960000367 inositol Drugs 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 230000001788 irregular Effects 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• 229920006008 lipopolysaccharide Polymers 0.000 description 2
• 206010024627 liposarcoma Diseases 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 229960002247 lomustine Drugs 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 201000005296 lung carcinoma Diseases 0.000 description 2
• 208000029791 lytic metastatic bone lesion Diseases 0.000 description 2
• 230000005291 magnetic effect Effects 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 208000027202 mammary Paget disease Diseases 0.000 description 2
• 229960001924 melphalan Drugs 0.000 description 2
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
• 229960001428 mercaptopurine Drugs 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• 229960004584 methylprednisolone Drugs 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 2
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 210000000066 myeloid cell Anatomy 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 208000007538 neurilemmoma Diseases 0.000 description 2
• 238000011580 nude mouse model Methods 0.000 description 2
• 208000016517 ovarian serous tumor Diseases 0.000 description 2
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
• 230000000242 pagocytic effect Effects 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
• 230000005298 paramagnetic effect Effects 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000006320 pegylation Effects 0.000 description 2
• 229940111202 pepsin Drugs 0.000 description 2
• 210000003200 peritoneal cavity Anatomy 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000001205 polyphosphate Substances 0.000 description 2
• 235000011176 polyphosphates Nutrition 0.000 description 2
• 229960004618 prednisone Drugs 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 229940097325 prolactin Drugs 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 150000003180 prostaglandins Chemical class 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000019254 respiratory burst Effects 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 229960000371 rofecoxib Drugs 0.000 description 2
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
• 230000001235 sensitizing effect Effects 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 125000005629 sialic acid group Chemical group 0.000 description 2
• 235000021309 simple sugar Nutrition 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 238000001542 size-exclusion chromatography Methods 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 201000005671 spondyloarthropathy Diseases 0.000 description 2
• 230000007480 spreading Effects 0.000 description 2
• 238000003892 spreading Methods 0.000 description 2
• 208000017572 squamous cell neoplasm Diseases 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000003637 steroidlike Effects 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000008093 supporting effect Effects 0.000 description 2
• 210000001258 synovial membrane Anatomy 0.000 description 2
• 206010042863 synovial sarcoma Diseases 0.000 description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 229940126585 therapeutic drug Drugs 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 206010044412 transitional cell carcinoma Diseases 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 229960002117 triamcinolone acetonide Drugs 0.000 description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 2
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 210000003932 urinary bladder Anatomy 0.000 description 2
• 230000002227 vasoactive effect Effects 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• MNHVIVWFCMBFCV-AVGNSLFASA-N (2S)-2-[[(2S)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-6-diazo-5-oxohexanoyl]amino]-6-diazo-5-oxohexanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(O)=O MNHVIVWFCMBFCV-AVGNSLFASA-N 0.000 description 1
• PAYBYKKERMGTSS-MNCSTQPFSA-N (2r,3r,3as,9ar)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 description 1
• LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
• NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
• RCFNNLSZHVHCEK-YGCMNLPTSA-N (7s,9s)-7-[(2s,4r,6s)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• OJRZEKJECRTBPJ-NGAMADIESA-N (z,5s)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
• FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
• SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
• ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
• OUSLUGWAQPNJKG-UHFFFAOYSA-N 1-aminodecan-2-one Chemical compound CCCCCCCCC(=O)CN OUSLUGWAQPNJKG-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
• KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
• QFDDBBKJOGTVNI-PVTQAGNOSA-N 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid;(1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;dihydrochloride Chemical compound Cl.Cl.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 QFDDBBKJOGTVNI-PVTQAGNOSA-N 0.000 description 1
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
• QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
• CIEMDIKTFOLQML-UHFFFAOYSA-N 2-amino-1-sulfanylethanol Chemical compound NCC(O)S CIEMDIKTFOLQML-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• 108050001326 26S Proteasome regulatory subunit 6A Proteins 0.000 description 1
• 102100029510 26S proteasome regulatory subunit 6A Human genes 0.000 description 1
• GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
• WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
• CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
• AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
• OMRLTNCLYHKQCK-DHGKCCLASA-N 4-nitrophenyl N-acetyl-beta-D-glucosaminide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([N+]([O-])=O)C=C1 OMRLTNCLYHKQCK-DHGKCCLASA-N 0.000 description 1
• 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
• PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1h-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
• KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
• ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 206010000599 Acromegaly Diseases 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 241000321096 Adenoides Species 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 208000008190 Agammaglobulinemia Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
• 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
• 108090000644 Angiozyme Proteins 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 102000004411 Antithrombin III Human genes 0.000 description 1
• 108090000935 Antithrombin III Proteins 0.000 description 1
• 101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 238000011729 BALB/c nude mouse Methods 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 208000035821 Benign schwannoma Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 229940122361 Bisphosphonate Drugs 0.000 description 1
• 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
• 206010065553 Bone marrow failure Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 206010055113 Breast cancer metastatic Diseases 0.000 description 1
• CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
• 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
• 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
• 102100032912 CD44 antigen Human genes 0.000 description 1
• 108010065524 CD52 Antigen Proteins 0.000 description 1
• 102100022002 CD59 glycoprotein Human genes 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• 101100231507 Caenorhabditis elegans ceh-2 gene Proteins 0.000 description 1
• 101100028482 Caenorhabditis elegans pal-1 gene Proteins 0.000 description 1
• 102000016843 Calbindin 2 Human genes 0.000 description 1
• 108010028326 Calbindin 2 Proteins 0.000 description 1
• 102100029968 Calreticulin Human genes 0.000 description 1
• 108090000549 Calreticulin Proteins 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 229910020194 CeH2 Inorganic materials 0.000 description 1
• 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
• 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
• 102100031186 Chromogranin-A Human genes 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 102100035176 Coiled-coil alpha-helical rod protein 1 Human genes 0.000 description 1
• 208000011038 Cold agglutinin disease Diseases 0.000 description 1
• 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
• HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• NBEALWAVEGMZQY-UHFFFAOYSA-N Enpromate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000160765 Erebia ligea Species 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
• 108010067306 Fibronectins Chemical group 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• 208000021309 Germ cell tumor Diseases 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 206010018404 Glucagonoma Diseases 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 108010022901 Heparin Lyase Proteins 0.000 description 1
• 206010019851 Hepatotoxicity Diseases 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 229910052689 Holmium Inorganic materials 0.000 description 1
• 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
• 101000798109 Homo sapiens Melanotransferrin Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
• 101000600766 Homo sapiens Podoplanin Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
• 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
• 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
• 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 241000257303 Hymenoptera Species 0.000 description 1
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
• 206010022004 Influenza like illness Diseases 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
• 102100026720 Interferon beta Human genes 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
• 206010073086 Iris melanoma Diseases 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 206010023203 Joint destruction Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
• 208000030514 Leukocyte adhesion deficiency type II Diseases 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 229910052765 Lutetium Inorganic materials 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
• 206010025538 Malignant ascites Diseases 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 229930126263 Maytansine Natural products 0.000 description 1
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
• 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
• 102100032239 Melanotransferrin Human genes 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 206010054949 Metaplasia Diseases 0.000 description 1
• 206010051676 Metastases to peritoneum Diseases 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
• ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 208000003445 Mouth Neoplasms Diseases 0.000 description 1
• 206010073101 Mucinous breast carcinoma Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101000985214 Mus musculus 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
• 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
• SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• FDJKUWYYUZCUJX-PGIATKPXSA-M N-glycoloylneuraminate Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C([O-])=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-PGIATKPXSA-M 0.000 description 1
• 238000011789 NOD SCID mouse Methods 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
• 206010029488 Nodular melanoma Diseases 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
• MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 102000038030 PI3Ks Human genes 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 206010053869 POEMS syndrome Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 101100365603 Phytophthora infestans (strain T30-4) SFI2 gene Proteins 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
• 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
• 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
• 102000010995 Pleckstrin homology domains Human genes 0.000 description 1
• 108050001185 Pleckstrin homology domains Proteins 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 229910052777 Praseodymium Inorganic materials 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
• 229910052773 Promethium Inorganic materials 0.000 description 1
• 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
• 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
• 102100038358 Prostate-specific antigen Human genes 0.000 description 1
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 208000009921 Rheumatoid Nodule Diseases 0.000 description 1
• 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 102000014400 SH2 domains Human genes 0.000 description 1
• 108050003452 SH2 domains Proteins 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
• 229910052772 Samarium Inorganic materials 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
• 102100038081 Signal transducer CD24 Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
• 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
• UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
• 102000000551 Syk Kinase Human genes 0.000 description 1
• 108010016672 Syk Kinase Proteins 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 206010073104 Tubular breast carcinoma Diseases 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 206010045240 Type I hypersensitivity Diseases 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 208000009311 VIPoma Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 206010047112 Vasculitides Diseases 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• FHNFHKCVQCLJFQ-NJFSPNSNSA-N Xenon-133 Chemical compound [133Xe] FHNFHKCVQCLJFQ-NJFSPNSNSA-N 0.000 description 1
• 208000012018 Yolk sac tumor Diseases 0.000 description 1
• 229910052769 Ytterbium Inorganic materials 0.000 description 1
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
• 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
• ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 1
• SPKNARKFCOPTSY-XWPZMVOTSA-N [(2r,3s)-2-[(2s,3r)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
• CJGYSWNGNKCJSB-YVLZZHOMSA-M [(4ar,6r,7r,7ar)-6-[6-(butanoylamino)purin-9-yl]-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-M 0.000 description 1
• ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 1
• NAFFDQVVNWTDJD-UHFFFAOYSA-L [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC1(C[NH-])CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 NAFFDQVVNWTDJD-UHFFFAOYSA-L 0.000 description 1
• JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 1
• IGCAUIJHGNYDKE-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC([O-])=O.CC([O-])=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCC[NH2+]CCO)=CC=C2NCC[NH2+]CCO IGCAUIJHGNYDKE-UHFFFAOYSA-N 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• QAWIHIJWNYOLBE-OKKQSCSOSA-N acivicin Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
• 229950008427 acivicin Drugs 0.000 description 1
• USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
• 229960004176 aclarubicin Drugs 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
• 229950000616 acronine Drugs 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 239000012082 adaptor molecule Substances 0.000 description 1
• 210000002534 adenoid Anatomy 0.000 description 1
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 229950004955 adozelesin Drugs 0.000 description 1
• BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 108700025316 aldesleukin Proteins 0.000 description 1
• 229960005310 aldesleukin Drugs 0.000 description 1
• 229940008201 allegra Drugs 0.000 description 1
• 229940060533 allegra-d Drugs 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
• 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
• ANBQYFIVLNNZCU-CQCLMDPOSA-N alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO)O2)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)[C@@H](NC(C)=O)[C@H](O[C@H]2[C@H]([C@@H](CO)O[C@@H](O)[C@@H]2O)O)O[C@@H]1CO ANBQYFIVLNNZCU-CQCLMDPOSA-N 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229950004821 ambomycin Drugs 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 230000003698 anagen phase Effects 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000003302 anti-idiotype Effects 0.000 description 1
• 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 238000011230 antibody-based therapy Methods 0.000 description 1
• 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229960005348 antithrombin iii Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 229940058060 astelin Drugs 0.000 description 1
• 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
• MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
• 208000006424 autoimmune oophoritis Diseases 0.000 description 1
• 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• HRXVDDOKERXBEY-UHFFFAOYSA-N azatepa Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
• 229960004574 azelastine Drugs 0.000 description 1
• 229950004295 azotomycin Drugs 0.000 description 1
• 229940064856 azulfidine Drugs 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 208000003373 basosquamous carcinoma Diseases 0.000 description 1
• XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
• 229950001858 batimastat Drugs 0.000 description 1
• 229940098032 beconase Drugs 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SMDHCQAYESWHAE-UHFFFAOYSA-N benfluralin Chemical compound CCCCN(CC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O SMDHCQAYESWHAE-UHFFFAOYSA-N 0.000 description 1
• 229950005567 benzodepa Drugs 0.000 description 1
• VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
• 229940125388 beta agonist Drugs 0.000 description 1
• CXQCLLQQYTUUKJ-ALWAHNIESA-N beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1<->1')-Cer(d18:1/18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 CXQCLLQQYTUUKJ-ALWAHNIESA-N 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 238000010256 biochemical assay Methods 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229950008548 bisantrene Drugs 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 150000004663 bisphosphonates Chemical class 0.000 description 1
• 229950006844 bizelesin Drugs 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 229960004395 bleomycin sulfate Drugs 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
• 208000018420 bone fibrosarcoma Diseases 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 201000007476 breast mucinous carcinoma Diseases 0.000 description 1
• 201000000135 breast papillary carcinoma Diseases 0.000 description 1
• 229950010231 brequinar Drugs 0.000 description 1
• PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
• PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 229950009494 bropirimine Drugs 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 108700002839 cactinomycin Proteins 0.000 description 1
• 229950009908 cactinomycin Drugs 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
• 229950009823 calusterone Drugs 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 238000009566 cancer vaccine Methods 0.000 description 1
• 229940022399 cancer vaccine Drugs 0.000 description 1
• 229950009338 caracemide Drugs 0.000 description 1
• 229950005155 carbetimer Drugs 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
• WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 229950001725 carubicin Drugs 0.000 description 1
• BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
• 229950007509 carzelesin Drugs 0.000 description 1
• 229950010667 cedefingol Drugs 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000004709 cell invasion Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
• 230000006364 cellular survival Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 229960001803 cetirizine Drugs 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• OWSKEUBOCMEJMI-KPXOXKRLSA-N chembl2105946 Chemical compound [N-]=[N+]=CC(=O)CC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CCC(=O)C=[N+]=[N-])C(O)=O OWSKEUBOCMEJMI-KPXOXKRLSA-N 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
• 229960003291 chlorphenamine Drugs 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
• 229940015047 chorionic gonadotropin Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 229950011359 cirolemycin Drugs 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 229940119122 clarinex Drugs 0.000 description 1
• 229940088529 claritin Drugs 0.000 description 1
• 229940070380 claritin-d Drugs 0.000 description 1
• 229910017052 cobalt Inorganic materials 0.000 description 1
• 239000010941 cobalt Substances 0.000 description 1
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000009096 combination chemotherapy Methods 0.000 description 1
• 229960005537 combretastatin A-4 Drugs 0.000 description 1
• HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
• 238000002967 competitive immunoassay Methods 0.000 description 1
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 101150002418 cpi-2 gene Proteins 0.000 description 1
• 230000002089 crippling effect Effects 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 201000003278 cryoglobulinemia Diseases 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 231100000409 cytocidal Toxicity 0.000 description 1
• 230000000445 cytocidal effect Effects 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 239000003145 cytotoxic factor Substances 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
• 229960003603 decitabine Drugs 0.000 description 1
• 229940075792 deconamine Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 229940027008 deltasone Drugs 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 229960001271 desloratadine Drugs 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
• 229950001640 dexormaplatin Drugs 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 229950010621 dezaguanine Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
• 229950002389 diaziquone Drugs 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• SVJSWELRJWVPQD-KJWOGLQMSA-L disodium;(2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-KJWOGLQMSA-L 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
• 229950004683 drostanolone propionate Drugs 0.000 description 1
• 229950005133 duazomycin Drugs 0.000 description 1
• 229930192837 duazomycin Natural products 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
• 229950006700 edatrexate Drugs 0.000 description 1
• 230000001909 effect on DNA Effects 0.000 description 1
• 229960002046 eflornithine hydrochloride Drugs 0.000 description 1
• 150000002066 eicosanoids Chemical class 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
• 229950002339 elsamitrucin Drugs 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 229940073621 enbrel Drugs 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 210000001900 endoderm Anatomy 0.000 description 1
• 208000001991 endodermal sinus tumor Diseases 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 229950010625 enloplatin Drugs 0.000 description 1
• 229950001022 enpromate Drugs 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 230000008995 epigenetic change Effects 0.000 description 1
• 229950004926 epipropidine Drugs 0.000 description 1
• 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 229950001426 erbulozole Drugs 0.000 description 1
• KLEPCGBEXOCIGS-QPPBQGQZSA-N erbulozole Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-QPPBQGQZSA-N 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
• IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
• WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
• 229950006566 etanidazole Drugs 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
• 229960000752 etoposide phosphate Drugs 0.000 description 1
• LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000010222 extracellular calcium influx Effects 0.000 description 1
• 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 229950011548 fadrozole Drugs 0.000 description 1
• 108010052621 fas Receptor Proteins 0.000 description 1
• 102000018823 fas Receptor Human genes 0.000 description 1
• NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 1
• 229950005096 fazarabine Drugs 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• 229950003662 fenretinide Drugs 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
• 239000012997 ficoll-paque Substances 0.000 description 1
• 210000001145 finger joint Anatomy 0.000 description 1
• 229940033835 flonase Drugs 0.000 description 1
• 229940085861 flovent Drugs 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• XSFJVAJPIHIPKU-XWCQMRHXSA-N flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 229950005682 flurocitabine Drugs 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• UXTSQCOOUJTIAC-UHFFFAOYSA-N fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
• 229950005611 fosquidone Drugs 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 229910052733 gallium Inorganic materials 0.000 description 1
• GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
• PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 1
• 150000002270 gangliosides Chemical class 0.000 description 1
• 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 201000005298 gastrointestinal allergy Diseases 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229910052732 germanium Inorganic materials 0.000 description 1
• GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
• 235000003969 glutathione Nutrition 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 229960002706 gusperimus Drugs 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 210000004247 hand Anatomy 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 231100000304 hepatotoxicity Toxicity 0.000 description 1
• 230000007686 hepatotoxicity Effects 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;n-methyl-n-[4-[(7-methyl-3h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 229960000930 hydroxyzine Drugs 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
• 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229950006905 ilmofosine Drugs 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 108010055790 immunoglobulin B Proteins 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000008676 import Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 229940125369 inhaled corticosteroids Drugs 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 150000002484 inorganic compounds Chemical class 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 102000030582 inositol polyphosphate 5-phosphatase Human genes 0.000 description 1
• 108060004006 inositol polyphosphate 5-phosphatase Proteins 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 229960003521 interferon alfa-2a Drugs 0.000 description 1
• 229960003507 interferon alfa-2b Drugs 0.000 description 1
• 229940109242 interferon alfa-n3 Drugs 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 229940117681 interleukin-12 Drugs 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 201000002696 invasive tubular breast carcinoma Diseases 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229950010897 iproplatin Drugs 0.000 description 1
• 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
• GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
• 201000002529 islet cell tumor Diseases 0.000 description 1
• 208000018934 joint symptom Diseases 0.000 description 1
• 210000005067 joint tissue Anatomy 0.000 description 1
• UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 210000000244 kidney pelvis Anatomy 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 108010021336 lanreotide Proteins 0.000 description 1
• 229960001739 lanreotide acetate Drugs 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 150000002611 lead compounds Chemical class 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 206010024217 lentigo Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 229960003088 loratadine Drugs 0.000 description 1
• XDMHALQMTPSGEA-UHFFFAOYSA-N losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
• 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
• 201000004593 malignant giant cell tumor Diseases 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 229950008959 marimastat Drugs 0.000 description 1
• OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
• 229960003951 masoprocol Drugs 0.000 description 1
• HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 208000000516 mast-cell leukemia Diseases 0.000 description 1
• 201000008749 mast-cell sarcoma Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
• 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
• QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229940064748 medrol Drugs 0.000 description 1
• 208000030163 medullary breast carcinoma Diseases 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960003846 melengestrol acetate Drugs 0.000 description 1
• 210000001806 memory b lymphocyte Anatomy 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 1
• 229950002676 menogaril Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
• 230000015689 metaplastic ossification Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 108010071421 milk fat globule Proteins 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 230000036456 mitotic arrest Effects 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229950000844 mizoribine Drugs 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 238000003032 molecular docking Methods 0.000 description 1
• 229940051875 mucins Drugs 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
• CRJGESKKUOMBCT-PMACEKPBSA-N n-[(2s,3s)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
• NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
• BSIZUMJRKYHEBR-QGZVFWFLSA-N n-hydroxy-2(r)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N([C@H](C(C)C)C(=O)NO)CC1=CC=CN=C1 BSIZUMJRKYHEBR-QGZVFWFLSA-N 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 229940002297 nasacort Drugs 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 229940089969 nasalcrom Drugs 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000019499 negative regulation of cell activation Effects 0.000 description 1
• 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
• 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 201000000032 nodular malignant melanoma Diseases 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 210000004882 non-tumor cell Anatomy 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 229960000470 omalizumab Drugs 0.000 description 1
• 230000003571 opsonizing effect Effects 0.000 description 1
• 229940124624 oral corticosteroid Drugs 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 229940029358 orthoclone okt3 Drugs 0.000 description 1
• 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 229960002739 oxaprozin Drugs 0.000 description 1
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 208000021255 pancreatic insulinoma Diseases 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229940097097 pediapred Drugs 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 208000010918 peritoneal neoplasm Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 201000003113 pineoblastoma Diseases 0.000 description 1
• 206010035059 pineocytoma Diseases 0.000 description 1
• 108010024226 placental ribonuclease inhibitor Proteins 0.000 description 1
• 208000031223 plasma cell leukemia Diseases 0.000 description 1
• 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 108700028325 pokeweed antiviral Proteins 0.000 description 1
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 102000035123 post-translationally modified proteins Human genes 0.000 description 1
• 108091005626 post-translationally modified proteins Proteins 0.000 description 1
• PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 229950003608 prinomastat Drugs 0.000 description 1
• YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical compound [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 230000009979 protective mechanism Effects 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 230000036647 reaction Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 229940107685 reopro Drugs 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 229910052702 rhenium Inorganic materials 0.000 description 1
• WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
• 229940072265 rhinocort Drugs 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229910052703 rhodium Inorganic materials 0.000 description 1
• 239000010948 rhodium Substances 0.000 description 1
• MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
• 102220241871 rs140296303 Human genes 0.000 description 1
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
• KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229910052706 scandium Inorganic materials 0.000 description 1
• SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 239000011669 selenium Substances 0.000 description 1
• 229940090585 serevent Drugs 0.000 description 1
• 230000007727 signaling mechanism Effects 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2r)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 1
• MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 210000001845 splenic macrophage Anatomy 0.000 description 1
• 229950001248 squalamine Drugs 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 229910052712 strontium Inorganic materials 0.000 description 1
• CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
• 229940089453 sudafed Drugs 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 208000030457 superficial spreading melanoma Diseases 0.000 description 1
• 239000013595 supernatant sample Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 201000010965 sweat gland carcinoma Diseases 0.000 description 1
• 229940036185 synagis Drugs 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 150000003595 thromboxanes Chemical class 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
• 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 230000030968 tissue homeostasis Effects 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 230000001228 trophic effect Effects 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 230000002476 tumorcidal effect Effects 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 108010060757 vasostatin Proteins 0.000 description 1
• 229950000578 vatalanib Drugs 0.000 description 1
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 208000008662 verrucous carcinoma Diseases 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229940079707 vistaril Drugs 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 210000000707 wrist Anatomy 0.000 description 1
• 210000003857 wrist joint Anatomy 0.000 description 1
• 229950004094 xenon (133xe) Drugs 0.000 description 1
• NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229940036139 zyrtec Drugs 0.000 description 1